Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 972587, 9 pages
http://dx.doi.org/10.1155/2014/972587
Research Article

Association of Tissue mRNA and Serum Antigen Levels of Members of the Urokinase-Type Plasminogen Activator System with Clinical and Prognostic Parameters in Prostate Cancer

1Urologische Klinik, Universitätsklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91052 Erlangen, Germany
2Klinik für Urologie, Technische Universität Dresden, 01307 Dresden, Germany
3Pathologisches Institut, Universitätsklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
4Department of Urology and Pediatric Urology, Julius-Maximilians-University, 97070 Würzburg, Germany
5Clinic of Urology, Caritas-Hospital St. Josef, 93053 Regensburg, Germany
6Institut für Pathologie, Technische Universität Dresden, 01307 Dresden, Germany
7Department of Obstetrics and Gynecology, Technical University of Munich, 81675 Munich, Germany

Received 13 August 2013; Accepted 21 March 2014; Published 29 April 2014

Academic Editor: Gerhard Unteregger

Copyright © 2014 Omar Al-Janabi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, H.-R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, vol. 127, no. 12, pp. 2893–2917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Miyake and M. Fujisawa, “Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches,” International Journal of Urology, vol. 20, no. 3, pp. 301–311, 2013. View at Google Scholar
  3. M. Truong, B. Yang, and D. F. Jarrard, “Toward the detection of prostate cancer in urine: a critical analysis,” Journal of Urology, vol. 189, no. 2, pp. 422–429, 2013. View at Google Scholar
  4. A. Mondino and F. Blasi, “uPA and uPAR in fibrinolysis, immunity and pathology,” Trends in Immunology, vol. 25, no. 8, pp. 450–455, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. B. McMahon and H. C. Kwaan, “The plasminogen activator system and cancer,” Pathophysiology of Haemostasis and Thrombosis, vol. 36, no. 3-4, pp. 184–194, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. M. J. Duffy, P. M. McGowan, and W. M. Gallagher, “Cancer invasion and metastasis: changing views,” Journal of Pathology, vol. 214, no. 3, pp. 283–293, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Mengele, R. Napieralski, V. Magdolen et al., “Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1,” Expert review of molecular diagnostics, vol. 10, no. 7, pp. 947–962, 2010. View at Google Scholar · View at Scopus
  8. M. J. Duffy, “The urokinase plasminogen activator system: role in malignancy,” Current Pharmaceutical Design, vol. 10, no. 1, pp. 39–49, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Dass, A. Ahmad, A. S. Azmi, S. H. Sarkar, and F. H. Sarkar, “Evolving role of uPA/uPAR system in human cancers,” Cancer Treatment Reviews, vol. 34, no. 2, pp. 122–136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. M. J. Duffy, T. M. Maguire, E. W. McDermott et al., “Urokinase plasminogen activator: a prognostic marker in multiple types of cancer,” Journal of Surgical Oncology, vol. 71, no. 2, pp. 130–135, 1999. View at Google Scholar
  11. M. Schmitt, N. Harbeck, C. Thomssen et al., “Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy,” Thrombosis and Haemostasis, vol. 78, no. 1, pp. 285–296, 1997. View at Google Scholar · View at Scopus
  12. M. Schmitt, K. Mengele, R. Napieralski et al., “Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1,” Expert Review of Molecular Diagnostics, vol. 10, no. 8, pp. 1051–1067, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. P. J. Cozzi, J. Wang, W. Delprado et al., “Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer,” Human Pathology, vol. 37, no. 11, pp. 1442–1451, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Kumano, H. Miyake, M. Muramaki, J. Furukawa, A. Takenaka, and M. Fujisawa, “Expression of urokinase-type plasminogen activator system in prostate cancer: Correlation with clinicopathological outcomes in patients undergoing radical prostatectomy,” Urologic Oncology, vol. 27, no. 2, pp. 180–186, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Gupta, Y. Lotan, R. Ashfaq et al., “Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients,” European Urology, vol. 55, no. 5, pp. 1124–1133, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. A. C. Riddick, C. J. Shukla, C. J. Pennington et al., “Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues,” British Journal of Cancer, vol. 92, no. 12, pp. 2171–2180, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Miyake, I. Hara, K. Yamanaka et al., “Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer,” Prostate, vol. 39, no. 2, pp. 123–129, 1999. View at Google Scholar
  18. S. F. Shariat, C. G. Roehrborn, J. D. McConnell et al., “Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis,” Journal of Clinical Oncology, vol. 25, no. 4, pp. 349–355, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. S. F. Shariat, J. A. Karam, J. Walz et al., “Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers,” Clinical Cancer Research, vol. 14, no. 12, pp. 3785–3791, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. C. E. Almasi, K. Brasso, P. Iversen et al., “Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer,” Prostate, vol. 71, no. 8, pp. 899–907, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Pilronen, A. Haese, H. Huland et al., “Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum,” Clinical Chemistry, vol. 52, no. 5, pp. 838–844, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Luther, M. Kotzsch, A. Meye et al., “Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer,” Thrombosis and Haemostasis, vol. 89, no. 4, pp. 705–717, 2003. View at Google Scholar · View at Scopus
  23. J. C. Biermann, L. Holzscheiter, M. Kotzsch et al., “Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA,” International Journal of Molecular Medicine, vol. 21, no. 2, pp. 251–259, 2008. View at Google Scholar · View at Scopus
  24. M. Kotzsch, V. Magdolen, T. Greither et al., “Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients,” BMC Cancer, vol. 11, article 273, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. P. A. Usher, O. F. Thomsen, P. Iversen et al., “Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue,” International Journal of Cancer, vol. 113, no. 6, pp. 870–880, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Gavrilov, O. Kenzior, M. Evans, R. Calaluce, and W. R. Folk, “Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers,” European Journal of Cancer, vol. 37, no. 8, pp. 1033–1040, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Spyratos, C. Bouchet, S. Tozlu et al., “Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer,” Anticancer Research, vol. 22, no. 5, pp. 2997–3003, 2002. View at Google Scholar · View at Scopus
  28. P. Urban, V. Vuaroqueaux, M. Labuhn et al., “Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer,” Journal of Clinical Oncology, vol. 24, no. 26, pp. 4245–4253, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Castelló, J. M. Landete, F. España et al., “Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer,” Thrombosis Research, vol. 120, no. 5, pp. 753–762, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Xue, C. J. Scarlett, C. J. Jackson, B. J. Allen, and R. C. Smith, “Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma,” Pancreas, vol. 36, no. 2, pp. 160–167, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. G. L. Semenza, “Targeting HIF-1 for cancer therapy,” Nature Reviews Cancer, vol. 3, no. 10, pp. 721–732, 2003. View at Google Scholar · View at Scopus
  32. N. Montgomery, A. Hill, S. McFarlane et al., “CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity,” Breast Cancer Research, vol. 14, no. 3, article R84, 2012. View at Publisher · View at Google Scholar
  33. U. Warnecke-Eberz, K. L. Prenzel, S. E. Baldus et al., “Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer,” Pancreas, vol. 36, no. 2, pp. 173–177, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. M. D. Sternlicht, A. M. Dunning, D. H. Moore et al., “Prognostic value of PAI1 in invasive breast cancer: Evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 11, pp. 2107–2114, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Leissner, T. Verjat, T. Bachelot et al., “Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer,” BMC Cancer, vol. 6, article 216, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Kotzsch, A. M. Sieuwerts, M. Grosser et al., “Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: Identification of rab31 as an independent prognostic factor,” Breast Cancer Research and Treatment, vol. 111, no. 2, pp. 229–240, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. I. D. Witzel, K. Milde-Langosch, R. M. Wirtz et al., “Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome,” Journal of Cancer Research and Clinical Oncology, vol. 136, no. 11, pp. 1709–1718, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Sakakibara, K. Hibi, M. Koike et al., “Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer,” Cancer Science, vol. 97, no. 5, pp. 395–399, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Sakakibara, K. Hibi, M. Koike et al., “Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer,” British Journal of Cancer, vol. 93, no. 7, pp. 799–803, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. L. Zhang, Z.-S. Zhao, G.-Q. Ru, and J. Ma, “Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer,” World Journal of Gastroenterology, vol. 12, no. 25, pp. 3970–3976, 2006. View at Google Scholar · View at Scopus
  41. G. Høyer-Hansen and I. K. Lund, “Urokinase receptor variants in tissue and body fluids,” Advances in Clinical Chemistry, vol. 44, pp. 65–102, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Taubert, P. Würl, T. Greither et al., “Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients,” British Journal of Cancer, vol. 102, no. 4, pp. 731–737, 2010. View at Publisher · View at Google Scholar · View at Scopus